Circulating serum microRNA-345 correlates with unfavorable pathological response to preoperative chemoradiotherapy in locally advanced rectal cancer
Metrics: PDF 1841 views | HTML 2204 views | ?
Jing Yu1, Ning Li1, Xin Wang1, Hua Ren1, Weihu Wang1, Shulian Wang1, Yongwen Song1, Yueping Liu1, Yexiong Li1, Xuantong Zhou2, Aiping Luo2, Zhihua Liu2, Jing Jin1
1Department of Radiation Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People’s Republic of China
2The State Key Laboratory of Molecular Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People’s Republic of China
Aiping Luo, email: [email protected]
Zhihua Liu, email: [email protected]
Jing Jin, email: [email protected]
Keywords: rectal cancer, preoperative chemoradiotherapy, serum mirna, personalized treatment
Received: March 22, 2016 Accepted: August 11, 2016 Published: August 27, 2016
Preoperative chemoradiotherapy (pre-CRT) has been represented as the standard treatment for locally advanced rectal cancer (LARC), but large variations of tumor radiation response to CRT have been reported in the clinic. To explore the function of microRNAs as potential therapeutic predictors of pre-CRT pathological response in LARC, we analyzed global miRNA expression in CRT-sensitive and CRT-resistant groups before treatment. MiR-345 was significantly elevated in the CRT-resistant group. Therefore, miR-345 was selected as a candidate for further analysis. We assessed the correlation between the miRNA signatures and the chemoradiotherapeutic response in 20 randomly selected LARC tissue samples (Validation set) and 87 serum samples (Training set) by qRT-PCR. Further, we validated the results in 42 randomly selected LARC serum samples (Validation set). High miR-345 expression was significantly correlated with unfavorable pre-CRT pathological response in tissue and serum. Moreover, low miR-345 levels predicted superior 3-year local recurrence free survival (LRFS). Taken together, circulating serum miR-345 correlates with unfavorable pre-CRT response and poor locoregional control in LARC. It might be a promising biomarker to facilitate patient stratification for personalized treatment.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.